Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
m |
||
| Line 14: | Line 14: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Subcutaneous medications]] | ||
[[Category:Anti-vWF medications]] | [[Category:Anti-vWF medications]] | ||
Revision as of 23:16, 23 February 2021
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2/6/2019: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi